On the public citation graph

Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

https://doi.org/10.1007/s00259-017-3678-4
0 signed · 234 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cncr.24796openalex-snapshot
177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
inferredcites →https://doi.org/10.1007/s00259-004-1571-4openalex-snapshot
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
inferredcites →https://doi.org/10.1007/s00259-008-0778-1openalex-snapshot
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
inferredcites →https://doi.org/10.1007/s00259-011-1833-xopenalex-snapshot
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
inferredcites →https://doi.org/10.1007/s00259-011-1902-1openalex-snapshot
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
inferredcites →https://doi.org/10.1007/s00259-013-2670-xopenalex-snapshot
Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy
inferredcites →https://doi.org/10.1007/s00259-014-2710-1openalex-snapshot
177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in India
inferredcites →https://doi.org/10.1007/s00259-014-2893-5openalex-snapshot
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
inferredcites →https://doi.org/10.1007/s00259-015-3001-1openalex-snapshot
Renal function affects absorbed dose to the kidneys and haematological toxicity during 177Lu-DOTATATE treatment
inferredcites →https://doi.org/10.1007/s00259-016-3382-9openalex-snapshot
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
inferredcites →https://doi.org/10.1016/j.ijrobp.2009.02.089openalex-snapshot
Radiation-Associated Kidney Injury
inferredcites →https://doi.org/10.1016/j.ijrobp.2009.07.1754openalex-snapshot
Use of Normal Tissue Complication Probability Models in the Clinic
inferredcites →https://doi.org/10.1053/j.semnuclmed.2016.04.006openalex-snapshot
Renal Function Assessment During Peptide Receptor Radionuclide Therapy
inferredcites →https://doi.org/10.1056/nejmoa1607427openalex-snapshot
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
inferredcites →https://doi.org/10.1088/0031-9155/58/5/1507openalex-snapshot
On the biologically effective dose (BED)—using convolution for calculating the effects of repair: I. Analytical considerations
inferredcites →https://doi.org/10.1088/0031-9155/58/5/1529openalex-snapshot
On the biologically effective dose (BED)—using convolution for calculating the effects of repair: II. Numerical considerations
inferredcites →https://doi.org/10.1088/0031-9155/60/21/8329openalex-snapshot
Uncertainty propagation for SPECT/CT-based renal dosimetry in177Lu peptide receptor radionuclide therapy
inferredcites →https://doi.org/10.1155/2012/320198openalex-snapshot
Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
inferredcites →https://doi.org/10.1159/000212381openalex-snapshot
Rate of Kidney Function Decline in Older Adults: A Comparison Using Creatinine and Cystatin C
inferredcites →https://doi.org/10.1200/jco.2007.15.2553openalex-snapshot
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
inferredcites →https://doi.org/10.1200/jco.2010.33.7873openalex-snapshot
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [ 90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
inferredcites →https://doi.org/10.1200/jco.2011.37.2151openalex-snapshot
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers
inferredcites →https://doi.org/10.2967/jnumed.108.053173openalex-snapshot
MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response—Implications for Radionuclide Therapy
inferredcites →https://doi.org/10.2967/jnumed.112.107524openalex-snapshot
Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177 Lu-DOTA-Octreotate Treatment
inferredcites →https://doi.org/10.2967/jnumed.115.159012openalex-snapshot
MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177 Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3958626openalex-extracted
Accuracy of Two Dosimetry Software Programs for 177Lu Radiopharmaceutical Therapy Using Voxel-Based Patient-Specific Phantoms
inferred← citeshttps://doi.org/10.1002/mp.13178openalex-snapshot
A method for tumor dosimetry based on hybrid planar‐SPECT/CT images and semiautomatic segmentation
inferred← citeshttps://doi.org/10.1002/mp.13846openalex-snapshot
Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy
inferred← citeshttps://doi.org/10.1002/mp.14375openalex-snapshot
Comparison of commercial dosimetric software platforms in patients treated with 177 Lu‐DOTATATE for peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1002/mp.15444openalex-snapshot
Comparison of voxel S ‐value methods for personalized voxel‐based dosimetry of 177 Lu‐DOTATATE
inferred← citeshttps://doi.org/10.1002/mp.16528openalex-snapshot
Averaging of absorbed doses: How matter matters
inferred← citeshttps://doi.org/10.1002/mp.16746openalex-snapshot
A radiomic‐ and dosiomic‐based machine learning regression model for pretreatment planning in 177Lu‐DOTATATE therapy
inferred← citeshttps://doi.org/10.1002/mp.16974openalex-snapshot
Simplified image‐based dosimetry using planar images and patient‐specific S‐values
inferred← citeshttps://doi.org/10.1002/mp.17852openalex-snapshot
Predicting [177Lu]Lu‐DOTA‐TATE dosimetry by using pre‐therapy [68Ga]Ga‐DOTA‐TATE PET/CT and biomarkers in patient with neuroendocrine tumors
inferred← citeshttps://doi.org/10.1007/978-3-030-65850-2_3openalex-snapshot
SPECT/CT for Dosimetry
inferred← citeshttps://doi.org/10.1007/978-3-030-72830-4_11openalex-snapshot
Radioreceptor Therapy
inferred← citeshttps://doi.org/10.1007/978-3-030-81261-4_15openalex-snapshot
Dosimetric Principles of Targeted Radiotherapy and Radioimmunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-031-05494-5_6openalex-snapshot
Radiobiology and Radiation Dosimetry in Nuclear Medicine
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_6-2openalex-snapshot
Radiobiology and Radiation Dosimetry in Nuclear Medicine
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_6-3openalex-snapshot
Radiobiology and Radiation Dosimetry in Nuclear Medicine
inferred← citeshttps://doi.org/10.1007/978-3-319-63067-0_34openalex-snapshot
PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s00259-017-3707-3openalex-snapshot
The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy
inferred← citeshttps://doi.org/10.1007/s00259-017-3859-1openalex-snapshot
From fixed activities to personalized treatments in radionuclide therapy: lost in translation?
inferred← citeshttps://doi.org/10.1007/s00259-018-3945-zopenalex-snapshot
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
inferred← citeshttps://doi.org/10.1007/s00259-018-4044-xopenalex-snapshot
Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning
inferred← citeshttps://doi.org/10.1007/s00259-018-4209-7openalex-snapshot
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
inferred← citeshttps://doi.org/10.1007/s00259-018-4221-yopenalex-snapshot
Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1007/s00259-019-04499-xopenalex-snapshot
Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours
inferred← citeshttps://doi.org/10.1007/s00259-019-04504-3openalex-snapshot
First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-021-05284-5openalex-snapshot
The increasing potential of nuclear medicine imaging for the evaluation and reduction of normal tissue toxicity from radiation treatments
inferred← citeshttps://doi.org/10.1007/s00259-021-05345-9openalex-snapshot
EANM position paper on the role of radiobiology in nuclear medicine
inferred← citeshttps://doi.org/10.1007/s00259-021-05583-xopenalex-snapshot
Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box
inferred← citeshttps://doi.org/10.1007/s00259-022-05727-7openalex-snapshot
EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
inferred← citeshttps://doi.org/10.1007/s00259-022-05786-wopenalex-snapshot
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
inferred← citeshttps://doi.org/10.1007/s00259-023-06383-1openalex-snapshot
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
inferred← citeshttps://doi.org/10.1007/s00259-024-06863-yopenalex-snapshot
The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE
inferred← citeshttps://doi.org/10.1007/s00259-025-07246-7openalex-snapshot
Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
inferred← citeshttps://doi.org/10.1007/s00259-026-07941-zopenalex-snapshot
Long-term toxicity of tandem radioligand therapy using [90Y]Y/[177Lu]Lu-DOTA-TATE in neuroendocrine tumors: a polish multicenter experience with 20-year follow-up
inferred← citeshttps://doi.org/10.1007/s00259-026-08126-4openalex-snapshot
Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1007/s00330-023-09697-8openalex-snapshot
Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1007/s00411-025-01137-zopenalex-snapshot
Human dose estimation of a novel SPECT imaging agent using animal experimental data and Monte Carlo simulation
inferred← citeshttps://doi.org/10.1007/s12194-025-00898-yopenalex-snapshot
A study of differences in absorbed dose estimates by images used in dosimetry of Lu-177-DOTATATE therapy
inferred← citeshttps://doi.org/10.1007/s12553-024-00867-2openalex-snapshot
Optimization of the number of post-therapeutic planar imaging time points for the most reliable organ and tumour dosimetry in peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1007/s13246-025-01551-zopenalex-snapshot
Feasibility of individual dosimetry using RT-PHITS for patients with SPECT/CT imaging after 177Lu-DOTATATE peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1007/s40336-021-00443-yopenalex-snapshot
Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications
inferred← citeshttps://doi.org/10.1007/s40336-023-00589-xopenalex-snapshot
Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
inferred← citeshttps://doi.org/10.1007/s40336-025-00685-0openalex-snapshot
The value of dosimetry in Peptide Receptor Radionuclide Therapy (PRRT) for neuroendocrine tumors: literature and practical aspects
inferred← citeshttps://doi.org/10.1007/s40336-026-00769-5openalex-snapshot
Radioligand therapy and tumor dosimetry: where are we and where are we going; are we in the era of personalized radioligand therapy?
inferred← citeshttps://doi.org/10.1007/s40618-024-02448-6openalex-snapshot
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian…
inferred← citeshttps://doi.org/10.1007/s42000-025-00733-4openalex-snapshot
Sex-dependent PRRT toxicity in patients with metastatic somatostatin receptor-avid neuroendocrine tumors treated with 177Lu-DOTATATE
inferred← citeshttps://doi.org/10.1016/b978-0-12-812512-0.00010-5openalex-snapshot
Role of Imaging in Early-Phase Trials
inferred← citeshttps://doi.org/10.1016/b978-0-12-822960-6.00173-3openalex-snapshot
Dosimetry with single photon emission tomography (SPECT)
inferred← citeshttps://doi.org/10.1016/b978-0-443-34199-1.00013-2openalex-snapshot
Theranostics in bone cancer
inferred← citeshttps://doi.org/10.1016/j.apradiso.2022.110459openalex-snapshot
Estimate of activity discharged into the sewer network in neuroendocrine treatments with 177Lu-DOTA-TATE
inferred← citeshttps://doi.org/10.1016/j.clon.2020.10.020openalex-snapshot
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
inferred← citeshttps://doi.org/10.1016/j.clon.2020.11.008openalex-snapshot
Multicentre Trials on Standardised Quantitative Imaging and Dosimetry for Radionuclide Therapies
inferred← citeshttps://doi.org/10.1016/j.clon.2020.12.002openalex-snapshot
Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy
inferred← citeshttps://doi.org/10.1016/j.coemr.2021.06.002openalex-snapshot
Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management
inferred← citeshttps://doi.org/10.1016/j.cpet.2022.11.002openalex-snapshot
Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment
inferred← citeshttps://doi.org/10.1016/j.eanmj.2026.100017openalex-snapshot
Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours
inferred← citeshttps://doi.org/10.1016/j.eanmj.2026.100245openalex-snapshot
Hybrid multi-timepoint/single-timepoint imaging for multi-cycle radiopharmaceutical therapy dosimetry: Performance in [177Lu]Lu-DOTATATE PRRT
inferred← citeshttps://doi.org/10.1016/j.ejmp.2018.11.001openalex-snapshot
A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
inferred← citeshttps://doi.org/10.1016/j.ejmp.2020.04.010openalex-snapshot
Validation of irtGPUMCD, a GPU-based Monte Carlo internal dosimetry framework for radionuclide therapy
inferred← citeshttps://doi.org/10.1016/j.ejmp.2021.07.001openalex-snapshot
Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN)
inferred← citeshttps://doi.org/10.1016/j.ejmp.2021.11.007openalex-snapshot
Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept
inferred← citeshttps://doi.org/10.1016/j.ejmp.2022.06.002openalex-snapshot
Is a single late SPECT/CT based kidney 177Lu-dosimetry superior to hybrid dosimetry with sequential multiple time-point whole-body planar scans in combination with an early SPECT/CT?
inferred← citeshttps://doi.org/10.1016/j.ejmp.2024.103335openalex-snapshot
Kidney dosimetry in [177Lu]Lu-DOTA-TATE therapy based on multiple small VOIs
inferred← citeshttps://doi.org/10.1016/j.ejmp.2026.105752openalex-snapshot
Recommendations for the dosimetry of patients undergoing therapy with radiopharmaceuticals that include 177Lu
inferred← citeshttps://doi.org/10.1016/j.eprac.2024.09.018openalex-snapshot
The University of Iowa Neuroendocrine Tumor Clinic
inferred← citeshttps://doi.org/10.1016/j.eururo.2022.05.025openalex-snapshot
Extensive 177Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy–like Picture
inferred← citeshttps://doi.org/10.1016/j.heliyon.2022.e09830openalex-snapshot
Accuracy of two dosimetry software programs for 177Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2020.08.026openalex-snapshot
Toward Individualized Voxel-Level Dosimetry for Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2020.08.035openalex-snapshot
Current Status of Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1016/j.ijrobp.2022.08.010openalex-snapshot
A Primer on Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1016/j.mednuc.2019.04.001openalex-snapshot
La radiothérapie interne vectorisée par les analogues de la somatostatine, en pratique, en 2019
inferred← citeshttps://doi.org/10.1016/j.mednuc.2020.02.008openalex-snapshot
Dosimétrie rénale du 177Lu-Dotatate : mise en place au sein du Groupement hospitalier Est des Hospices Civils de Lyon
inferred← citeshttps://doi.org/10.1016/j.nucmedbio.2022.02.004openalex-snapshot
Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
inferred← citeshttps://doi.org/10.1016/j.remn.2021.02.006openalex-snapshot
Descripción de la metodología para la cuantificación dosimétrica en tratamientos con 177Lu-DOTATATE
inferred← citeshttps://doi.org/10.1016/j.remn.2024.500089openalex-snapshot
Análisis de variables dosimétricas y clínicas en el tratamiento de los tumores neuroendocrinos con [177Lu]Lu-DOTA-TATE
inferred← citeshttps://doi.org/10.1016/j.remnie.2021.03.022openalex-snapshot
Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE
inferred← citeshttps://doi.org/10.1016/j.remnie.2024.500089openalex-snapshot
Analysis of dosimetry and clinical variables in treatments of neuroendocrine tumours with [177Lu]Lu-DOTA-TATE
inferred← citeshttps://doi.org/10.1016/j.semradonc.2020.07.009openalex-snapshot
Radiopharmaceutical Delivery for Theranostics: Pharmacokinetics and Pharmacodynamics
inferred← citeshttps://doi.org/10.1016/j.soc.2019.11.005openalex-snapshot
Overview and Current Status of Peptide Receptor Radionuclide Therapy
inferred← citeshttps://doi.org/10.1016/j.zemedi.2018.12.001openalex-snapshot
A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy
inferred← citeshttps://doi.org/10.1016/j.zemedi.2023.02.006openalex-snapshot
Heterogeneity of absorbed dose distribution in kidney tissues and dose–response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review
inferred← citeshttps://doi.org/10.1016/s1470-2045(21)00657-4openalex-snapshot
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
inferred← citeshttps://doi.org/10.1021/acs.chemrev.8b00294openalex-snapshot
Radioactive Main Group and Rare Earth Metals for Imaging and Therapy
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.6c00029openalex-snapshot
Preclinical Safety Evaluation and First-in-Human Translational Study of [ 177 Lu]Lu-TEFAPI-06: An Albumin-Binding Fibroblast Activation Protein Inhibitor for Theranostics
inferred← citeshttps://doi.org/10.1038/s41598-026-36823-5openalex-snapshot
Global insights into [177Lu]Lu-DOTATATE safety: a comprehensive disproportionality analysis from the WHO pharmacovigilance database
inferred← citeshttps://doi.org/10.1038/s41598-026-61293-0openalex-snapshot
Assessment of potential nephrotoxicity biomarkers after [177Lu]Lu-DOTA-(Tyr3)-octreotate administration and effects of antioxidant α1-microglobulin
inferred← citeshttps://doi.org/10.1039/9781837677139-00159openalex-snapshot
Dosimetry Methods for Radiopharmaceuticals
inferred← citeshttps://doi.org/10.1053/j.ro.2025.04.005openalex-snapshot
Lutetium-177 Theranostics and Dosimetry for Neuroendocrine Neoplasms and Prostate Cancer
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2021.11.004openalex-snapshot
Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy
inferred← citeshttps://doi.org/10.1055/a-1556-8361openalex-snapshot
Bild-basierte Patienten-individuelle Dosimetrie bei internen Radionuklidtherapien von neuroendokrinen Tumoren
inferred← citeshttps://doi.org/10.1055/a-1802-8504openalex-snapshot
Dosimetrie bei der Peptid-Radio-Rezeptor-Therapie (PRRT)
inferred← citeshttps://doi.org/10.1055/a-2200-2145openalex-snapshot
Artificial Intelligence-powered automatic volume calculation in medical images – available tools, performance and challenges for nuclear medicine
inferred← citeshttps://doi.org/10.1080/0284186x.2021.1959635openalex-snapshot
Myelosuppression in patients treated with177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
inferred← citeshttps://doi.org/10.1080/14656566.2026.2735443openalex-snapshot
New and emerging somatostatin therapies for neuroendocrine tumors: “what is in the pipeline”
inferred← citeshttps://doi.org/10.1088/1361-6560/ab3039openalex-snapshot
Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177 Lu-DOTATATE patient study
inferred← citeshttps://doi.org/10.1088/1361-6560/abc707openalex-snapshot
IPEM topical report: current molecular radiotherapy service provision and guidance on the implications of setting up a dosimetry service
inferred← citeshttps://doi.org/10.1088/1361-6560/ac46e0openalex-snapshot
Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy
inferred← citeshttps://doi.org/10.1088/1361-6560/aea39bopenalex-snapshot
Learning-enhanced hybrid planar-SPECT dosimetry for voxel-level Monte Carlo dose estimation in radionuclide therapy
inferred← citeshttps://doi.org/10.1093/ndt/gfaf121openalex-snapshot
Peptide receptor radionuclide therapy: a new era of radiation nephropathy
inferred← citeshttps://doi.org/10.1093/rpd/ncab079openalex-snapshot
ACTIVITY CONCENTRATION ESTIMATION IN AUTOMATED KIDNEY SEGMENTATION BASED ON CONVOLUTION NEURAL NETWORK METHOD FOR 177LU–SPECT/CT KIDNEY DOSIMETRY
inferred← citeshttps://doi.org/10.1093/rpd/ncaf123openalex-snapshot
Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach
inferred← citeshttps://doi.org/10.1097/mnm.0000000000001198openalex-snapshot
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review
inferred← citeshttps://doi.org/10.1097/mnm.0000000000001472openalex-snapshot
Analysis of absorbed dose in radioimmunotherapy with 177Lu-trastuzumab using two different imaging scenarios: a pilot study
inferred← citeshttps://doi.org/10.1097/mnm.0000000000001835openalex-snapshot
Quantifying partial volume effect in SPECT and planar imaging: optimizing region of interest for activity concentration estimation in different sphere sizes
inferred← citeshttps://doi.org/10.1097/rlu.0000000000003667openalex-snapshot
Safety of Fibroblast Activation Protein–Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04
inferred← citeshttps://doi.org/10.1097/rlu.0000000000004599openalex-snapshot
177Lu-DOTATATE Theranostics
inferred← citeshttps://doi.org/10.1097/rlu.0000000000005330openalex-snapshot
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.1109/tci.2023.3318993openalex-snapshot
SPECT Reconstruction With a Trained Regularizer Using CT-Side Information: Application to $^{177}$Lu SPECT Imaging
inferred← citeshttps://doi.org/10.1109/trpms.2018.2860563openalex-snapshot
3-D Image-Based Dosimetry in Radionuclide Therapy
inferred← citeshttps://doi.org/10.1111/jne.13088openalex-snapshot
Treatment of neuroendocrine tumours with 177 Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management
inferred← citeshttps://doi.org/10.1148/rycan.220157openalex-snapshot
A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements
inferred← citeshttps://doi.org/10.1159/000507761openalex-snapshot
Pituitary Function after High-Dose 177Lu-DOTATATE Therapy and Long-Term Follow-Up
inferred← citeshttps://doi.org/10.1177/0146645319838665openalex-snapshot
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
inferred← citeshttps://doi.org/10.1177/10849785261465837openalex-snapshot
Personalized Radionuclide Therapy via Avidin-Biotin Pretargeting: Biodistribution and Dosimetry of 177 Lu-DOTA-biotin with AvidinOX TM in Solid Tumors
inferred← citeshttps://doi.org/10.1177/14736691211060117openalex-snapshot
ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1177/1559325821990147openalex-snapshot
177 Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Indigenously Developed Freeze Dried Cold Kit and Biological Response in In-Vitro and In-Vivo Models
inferred← citeshttps://doi.org/10.1186/s12885-022-10443-4openalex-snapshot
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)
inferred← citeshttps://doi.org/10.1186/s13550-018-0443-zopenalex-snapshot
Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
inferred← citeshttps://doi.org/10.1186/s13550-018-0459-4openalex-snapshot
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
inferred← citeshttps://doi.org/10.1186/s13550-020-00623-3openalex-snapshot
PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
inferred← citeshttps://doi.org/10.1186/s13550-025-01284-wopenalex-snapshot
Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
inferred← citeshttps://doi.org/10.1186/s40658-017-0193-4openalex-snapshot
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
inferred← citeshttps://doi.org/10.1186/s40658-017-0194-3openalex-snapshot
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
inferred← citeshttps://doi.org/10.1186/s40658-018-0210-2openalex-snapshot
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1186/s40658-018-0219-6openalex-snapshot
Validation of gallbladder absorbed radiation dose reduction simulation: human dosimetry of [18F]fluortriopride
inferred← citeshttps://doi.org/10.1186/s40658-018-0224-9openalex-snapshot
Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT
inferred← citeshttps://doi.org/10.1186/s40658-018-0232-9openalex-snapshot
Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (‘Lutate’) therapy
inferred← citeshttps://doi.org/10.1186/s40658-020-00308-9openalex-snapshot
A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1186/s40658-020-00311-0openalex-snapshot
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
inferred← citeshttps://doi.org/10.1186/s40658-020-00328-5openalex-snapshot
Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy
inferred← citeshttps://doi.org/10.1186/s40658-020-00339-2openalex-snapshot
Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
inferred← citeshttps://doi.org/10.1186/s40658-020-0275-6openalex-snapshot
Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction
inferred← citeshttps://doi.org/10.1186/s40658-021-00385-4openalex-snapshot
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy
inferred← citeshttps://doi.org/10.1186/s40658-021-00397-0openalex-snapshot
A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project
inferred← citeshttps://doi.org/10.1186/s40658-021-00421-3openalex-snapshot
Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems
inferred← citeshttps://doi.org/10.1186/s40658-021-00422-2openalex-snapshot
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
inferred← citeshttps://doi.org/10.1186/s40658-022-00462-2openalex-snapshot
Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for $$^{177}$$Lu-DOTATATE therapy
inferred← citeshttps://doi.org/10.1186/s40658-022-00473-zopenalex-snapshot
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.1186/s40658-022-00484-wopenalex-snapshot
Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
inferred← citeshttps://doi.org/10.1186/s40658-023-00602-2openalex-snapshot
Feasibility of 177Lu activity quantification using a small portable CZT-based gamma-camera
inferred← citeshttps://doi.org/10.1186/s40658-024-00612-8openalex-snapshot
Anatomy-based correction of kidney PVE on $$^{177}\text{Lu}$$ SPECT images
inferred← citeshttps://doi.org/10.1186/s40658-024-00658-8openalex-snapshot
A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?
inferred← citeshttps://doi.org/10.1186/s40658-024-00665-9openalex-snapshot
Estimation of kidney doses from [177Lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT/CT
inferred← citeshttps://doi.org/10.1186/s40658-024-00672-wopenalex-snapshot
Dosimetric implications of kidney anatomical volume changes in 177Lu-DOTATATE therapy
inferred← citeshttps://doi.org/10.1186/s40658-025-00764-1openalex-snapshot
Toward the standardization of radiopharmaceutical therapies: a technical note evaluating a clinical dosimetry workflow for single-time-point 177Lu SPECT/CT-based therapies
inferred← citeshttps://doi.org/10.1186/s40658-025-00769-wopenalex-snapshot
Evaluation of using small volume of interest regions for clinical kidney dosimetry in 177Lu-DOTATATE treatments
inferred← citeshttps://doi.org/10.1186/s40658-026-00897-xopenalex-snapshot
Evaluation of segmentation accuracy and the improvement of time effectiveness using deep learning-based segmentation in 177Lu-DOTATATE dosimetry
inferred← citeshttps://doi.org/10.1200/jco.23.01241openalex-snapshot
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
inferred← citeshttps://doi.org/10.1259/bjr.20210403openalex-snapshot
Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease
inferred← citeshttps://doi.org/10.1259/bjr.20210547openalex-snapshot
The internal dosimetry user group position statement on molecular radiotherapy
inferred← citeshttps://doi.org/10.1259/bjr.20220056openalex-snapshot
Milestones in dosimetry for nuclear medicine therapy
inferred← citeshttps://doi.org/10.15126/thesis.00853911openalex-snapshot
Metrology for Quantitative Imaging and Molecular Radiotherapy
inferred← citeshttps://doi.org/10.1530/erc-19-0165openalex-snapshot
Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups
inferred← citeshttps://doi.org/10.21037/qims-20-1006openalex-snapshot
Recent advances in voxel-based targeted radionuclide therapy dosimetry
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1514915/v1openalex-snapshot
Impact of the dead-time correction method on quantitative 177Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy
inferred← citeshttps://doi.org/10.22038/aojnmb.2022.63827.1448openalex-snapshot
Partial volume effect in SPECT & PET imaging and impact on radionuclide dosimetry estimates.
inferred← citeshttps://doi.org/10.23736/s1824-4785.20.03266-5openalex-snapshot
Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225
inferred← citeshttps://doi.org/10.23736/s1824-4785.21.03418-xopenalex-snapshot
Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization
inferred← citeshttps://doi.org/10.2967/jnumed.117.202903openalex-snapshot
90Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy
inferred← citeshttps://doi.org/10.2967/jnumed.118.225235openalex-snapshot
Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177 Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
inferred← citeshttps://doi.org/10.2967/jnumed.120.245548openalex-snapshot
Deep-Learning Generation of Synthetic Intermediate Projections Improves 177Lu SPECT Images Reconstructed with Sparsely Acquired Projections
inferred← citeshttps://doi.org/10.2967/jnumed.120.256255openalex-snapshot
A Novel Time–Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE
inferred← citeshttps://doi.org/10.2967/jnumed.121.262069openalex-snapshot
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177 Lu-DOTATATE
inferred← citeshttps://doi.org/10.2967/jnumed.121.262750openalex-snapshot
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
inferred← citeshttps://doi.org/10.2967/jnumed.121.262754openalex-snapshot
Dosimetry for Radiopharmaceutical Therapy: The European Perspective
inferred← citeshttps://doi.org/10.2967/jnumed.121.262977openalex-snapshot
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice
inferred← citeshttps://doi.org/10.2967/jnumed.121.263056openalex-snapshot
Safety of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients with Chronic Kidney Disease
inferred← citeshttps://doi.org/10.2967/jnumed.121.263738openalex-snapshot
A pipeline for automated voxel dosimetry: application in patients with multi-SPECT/CT imaging following 177 Lu peptide receptor radionuclide therapy
inferred← citeshttps://doi.org/10.2967/jnumed.122.264923openalex-snapshot
Impact of Single-Time-Point Estimates of177Lu-PRRT Absorbed Doses on Patient Management: Validation of a Trained Multiple-Linear-Regression Model in 159 Patients and 477 Therapy Cycles
inferred← citeshttps://doi.org/10.2967/jnumed.122.265338openalex-snapshot
Single-Time-Point Imaging for Dosimetry After [177Lu]Lu-DOTATATE: Accuracy of Existing Methods and Novel Data-Driven Models for Reducing Sensitivity to Time-Point Selection
inferred← citeshttps://doi.org/10.2967/jnumed.123.265986openalex-snapshot
Long-Term Nephrotoxicity of177Lu-PSMA Radioligand Therapy
inferred← citeshttps://doi.org/10.2967/jnumed.123.266619openalex-snapshot
Safety and Efficacy ofPara-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.2967/jnumed.124.269098openalex-snapshot
Can177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
inferred← citeshttps://doi.org/10.2967/jnumed.124.269378openalex-snapshot
Rethinking Dosimetry: A European Perspective
inferred← citeshttps://doi.org/10.2967/jnumed.124.269389openalex-snapshot
Multicycle Dosimetric Behavior and Dose–Effect Relationships in [177Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy
inferred← citeshttps://doi.org/10.2967/jnumed.125.270979openalex-snapshot
Summary: SNMMI/ACNM Procedure Standard for Posttreatment Imaging of 177 Lu-Based Radiopharmaceuticals
inferred← citeshttps://doi.org/10.2967/jnumed.125.271564openalex-snapshot
Toward Personalized Radiopharmaceutical Therapy: Radiobiologic Insights Compared with External-Beam Radiotherapy
inferred← citeshttps://doi.org/10.30895/1991-2919-2025-15-1-105-120openalex-snapshot
Planning a Clinical Development Programme for Radiopharmaceuticals: An Analysis of International Guidelines and Expertise
inferred← citeshttps://doi.org/10.33266/1024-6177-2026-71-5-65-72openalex-snapshot
Evaluation of Radiation Safety of Radiopharmaceutical Based on 177Lu-Dota-PSMA in the Treatment of Metastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.33540/334openalex-snapshot
Spicing up prostate cancer theranostics
inferred← citeshttps://doi.org/10.3389/fnume.2023.1209823openalex-snapshot
Biodosimetry, can it find its way to the nuclear medicine clinic?
inferred← citeshttps://doi.org/10.3389/fnume.2024.1355912openalex-snapshot
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
inferred← citeshttps://doi.org/10.3389/fonc.2023.1141648openalex-snapshot
Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.3390/cancers11101412openalex-snapshot
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
inferred← citeshttps://doi.org/10.3390/cancers14010129openalex-snapshot
Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies
inferred← citeshttps://doi.org/10.3390/cancers14041055openalex-snapshot
Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
inferred← citeshttps://doi.org/10.3390/cancers14143418openalex-snapshot
Individualization of Radionuclide Therapies: Challenges and Prospects
inferred← citeshttps://doi.org/10.3390/cancers15030915openalex-snapshot
In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib
inferred← citeshttps://doi.org/10.3390/cancers15184605openalex-snapshot
Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
inferred← citeshttps://doi.org/10.3390/diagnostics12071763openalex-snapshot
Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer
inferred← citeshttps://doi.org/10.3390/ijms22158326openalex-snapshot
Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead
inferred← citeshttps://doi.org/10.3390/ph19050774openalex-snapshot
Biological Sex Influences the Pharmacokinetics and Organ Dosimetry of 177Lu-DOTATATE: A Systematic Preclinical Evaluation
inferred← citeshttps://doi.org/10.3390/pharmaceutics15041110openalex-snapshot
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE
inferred← citeshttps://doi.org/10.3390/pharmaceutics15041240openalex-snapshot
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
inferred← citeshttps://doi.org/10.3390/radiation6030035openalex-snapshot
Theranostics in Pancreatic Neuroendocrine Neoplasms: From Molecular Imaging to Personalized Radionuclide Therapy
inferred← citeshttps://doi.org/10.37004/sefm/2024.25.2.003openalex-snapshot
Procedimiento recomendado para la dosimetría de pacientes en terapia con radiofármacos que incluyen 177Lu
inferred← citeshttps://doi.org/10.37336/2707-0700-2021-4-3openalex-snapshot
The role of modern methods of nuclear medicine in the diagnosis of radiation disease in patients after radiation and radionuclide therapy
inferred← citeshttps://doi.org/10.4103/jmp.jmp_82_21openalex-snapshot
Does Single Computed Tomography Attenuation Correction able to Surrogate Serial Computed Tomography Attenuation Correction in Single-Photon Emission Computed Therapy Imaging for Peptide Receptor Radionuclide Therapy Dosimetry Result?
inferred← citeshttps://doi.org/10.4274/nts.galenos.2019.0029openalex-snapshot
Renal Toxicity After Radionuclide Therapy
inferred← citeshttps://doi.org/10.4274/nts.galenos.2021.0033openalex-snapshot
Is Dosimetry Necessary in the Treatment of PRRT?
inferred← citeshttps://doi.org/10.52717/etgd4467openalex-snapshot
Hybrid Imaging in conventional nuclear medicine
showing the first 200 of 209
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.